We advised the joint book-running managers on the offering

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $1 billion aggregate principal amount of floating-rate notes due 2029, $2.25 billion aggregate principal amount of 3.700% notes due 2029, $2.5 billion aggregate principal amount of 4.000% notes due 2031, $2.75 billion aggregate principal amount of 4.300% notes due 2033, $3.75 billion aggregate principal amount of 4.650% notes due 2036, $2 billion aggregate principal amount of 4.750% notes due 2038, $3.75 billion aggregate principal amount of 5.500% notes due 2056, and $2 billion aggregate principal amount of 5.600% notes due 2066. The net proceeds from the offering will be used to fund Abbott’s pending acquisition of Exact Sciences Corporation, to repay certain indebtedness of Exact Sciences, to pay related fees and expenses, and for general corporate purposes, which may include, without limitation, the repayment of indebtedness.

Abbott is a global healthcare company that researches and manufactures a range of medical technologies. With a portfolio of leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines, Abbott serves people in more than 160 countries and employs approximately 115,000 people globally.

The Davis Polk capital markets team included partner Roshni Banker Cariello and associates Fei Deng and Muxuan (Muriel) Wang. Counsel Michael Comstock provided environmental advice. Partner Ethan R. Goldman and associate Fred (Chen) Fu provided tax advice. Partner Frank Azzopardi and associates Brette L. Trost and Anne Kim provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post